Analysts Set OnKure Therapeutics, Inc. (NASDAQ:OKUR) Target Price at $32.00

OnKure Therapeutics, Inc. (NASDAQ:OKUR) has been assigned an average recommendation of “Hold” from the five research firms that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $32.00.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of OnKure Therapeutics in a research note on Monday, December 22nd.

Institutional Trading of OnKure Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Acorn Capital Advisors LLC raised its position in OnKure Therapeutics by 97.2% in the second quarter. Acorn Capital Advisors LLC now owns 2,839,674 shares of the company’s stock worth $6,787,000 after acquiring an additional 1,400,000 shares during the period. Highbridge Capital Management LLC grew its position in shares of OnKure Therapeutics by 51.2% during the 2nd quarter. Highbridge Capital Management LLC now owns 663,607 shares of the company’s stock valued at $1,586,000 after acquiring an additional 224,810 shares during the period. Bailard Inc. purchased a new stake in shares of OnKure Therapeutics during the 2nd quarter worth approximately $34,000. Shay Capital LLC increased its stake in shares of OnKure Therapeutics by 417.8% during the 2nd quarter. Shay Capital LLC now owns 782,046 shares of the company’s stock worth $1,869,000 after purchasing an additional 631,008 shares during the last quarter. Finally, Renaissance Technologies LLC raised its holdings in shares of OnKure Therapeutics by 40.7% in the 4th quarter. Renaissance Technologies LLC now owns 247,350 shares of the company’s stock worth $717,000 after purchasing an additional 71,600 shares during the period. Hedge funds and other institutional investors own 90.98% of the company’s stock.

OnKure Therapeutics Trading Up 11.5%

OKUR stock opened at $3.40 on Friday. The stock has a market cap of $46.07 million, a P/E ratio of -0.71 and a beta of 0.45. The stock’s fifty day simple moving average is $2.78 and its two-hundred day simple moving average is $2.85. OnKure Therapeutics has a 1-year low of $1.70 and a 1-year high of $5.32.

OnKure Therapeutics Company Profile

OnKure Therapeutics, Inc (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.

The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.